Analysts Offer Insights on Healthcare Companies: Agios Pharma (NASDAQ: AGIO) and Shire (NASDAQ: SHPG)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agios Pharma (NASDAQ: AGIO) and Shire (NASDAQ: SHPG) with bullish sentiments.

Agios Pharma (NASDAQ: AGIO)

In a report released today, Eric Schmidt from Cowen & Co. reiterated a Buy rating on Agios Pharma (NASDAQ: AGIO). The company’s shares opened today at $47.63.

Schmidt said:

“Agios ended Q3 with $623MM in cash, enough to last through 2018.”

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 11.6% and a 38.3% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.

Currently, the analyst consensus on Agios Pharma is Strong Buy and the average price target is $70, representing a 47.0% upside.

In a report issued on October 24, Needham also initiated coverage with a Buy rating on the stock with a $60 price target.
Shire (NASDAQ: SHPG)

In a report released today, Ken Cacciatore from Cowen & Co. reiterated a Buy rating on Shire (NASDAQ: SHPG), with a price target of $325. The company’s shares opened today at $166.38.

Cacciatore noted:

“We continue to believe that the risks to the Shire story are exhaustingly well.”

According to TipRanks.com, Cacciatore is a 4-star analyst with an average return of 4.8% and a 33.3% success rate. Cacciatore covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Amag Pharmaceuticals, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Shire is Strong Buy and the average price target is $283.50, representing a 70.4% upside.

In a report issued on November 1, BTIG also maintained a Buy rating on the stock with a $242 price target.